HGH Peptides vs Recombinant HGH: Two Different Drugs, Compared
'HGH peptides' (GH secretagogues) prompt the pituitary to release growth hormone. Recombinant HGH is that hormone itself, FDA-approved for defined deficiencies only.
The short version
GH secretagogues (sermorelin, CJC-1295, ipamorelin and tesamorelin) prompt the pituitary to release the body's own growth hormone. Recombinant human growth hormone (somatropin) is that hormone itself, manufactured and injected directly. Only tesamorelin and recombinant HGH are currently FDA-approved. Each is approved for defined conditions, never for general muscle, sleep or anti-aging use in healthy adults.
- GH secretagogues prompt the pituitary to release its own growth hormone. Recombinant HGH is growth hormone itself, injected directly.
- Only tesamorelin and recombinant HGH are currently FDA-approved, each for one defined condition, not general muscle, sleep or anti-aging use.
- Sermorelin was approved once, for children with growth hormone deficiency, and discontinued by its maker in 2008. FDA found in 2013 it was not withdrawn for safety or effectiveness.
- CJC-1295 and ipamorelin have never been approved anywhere and are sold as research chemicals.
- All of them are named on the WADA Prohibited List and are prohibited in sport at all times.
Vendors sell “HGH peptides” and HGH itself as if choosing between them were a matter of preference. They are not interchangeable products. “HGH peptides” are GH secretagogues, not HGH. One group signals the pituitary to release more of the growth hormone the body already makes. The other is that hormone, manufactured and injected directly. This page compares the two mechanisms, and the four secretagogues most often sold as “HGH peptides” (sermorelin, CJC-1295, ipamorelin and tesamorelin), against recombinant human growth hormone.
Side by side: two different mechanisms
| GH secretagogues | Recombinant HGH | |
|---|---|---|
| What it is | Peptides that act on a pituitary receptor - the GHRH receptor or the ghrelin receptor | Somatropin: a manufactured protein with the same amino acid sequence as pituitary-derived human growth hormone |
| Mechanism | Signals the pituitary to release its own stored growth hormone | Supplies growth hormone directly; the pituitary step is bypassed |
| Feedback loop | Somatostatin and pulsatile release patterns stay intact, in principle | Bypassed - the body is not the one deciding how much to release or when |
| FDA-approved today | Only tesamorelin, for one narrow indication | Yes, multiple brands, for defined deficiency states |
| Sold to healthy adults for | Muscle, sleep, anti-aging, energy - none of these are approved uses for any of the four | Off-label and grey-market use for the same claims - also not approved uses |
| WADA 2026 | S2.2.4, growth hormone releasing factor | S2.2.3, growth hormone |
Full pages: Sermorelin · CJC-1295 · Ipamorelin · Tesamorelin
The four secretagogues, one at a time
They do not share a regulatory history. Grouping them as “GH peptides” hides that three of the four have never been approved for anything.
| Sermorelin | CJC-1295 | Ipamorelin | Tesamorelin | |
|---|---|---|---|---|
| Class | GHRH(1-29) analogue | GHRH(1-29) analogue, with or without an albumin-binding DAC group | Pentapeptide, ghrelin receptor agonist | Full-length GHRH(1-44) analogue |
| FDA history | Approved 1990 and 1997 (GEREF), discontinued by the sponsor in 2008, approvals withdrawn 2009 | Reached Phase 2, discontinued, never approved | Reached Phase 2 for postoperative ileus, discontinued for insufficient efficacy, never approved | Approved 2010 as Egrifta, still approved |
| Current US status | Research-only / compounded | Research-only | Research-only | Rx-approved |
| Evidence level on this site | Limited | Limited | Limited | Strong (for its one indication) |
| WADA 2026 | S2.2.4 | S2.2.4 | S2.2.4 | S2.2.4 |
Full detail: Sermorelin vs ipamorelin · CJC-1295 vs sermorelin · Tesamorelin vs sermorelin
Why “raises GH” is not “is GH”
Sermorelin, CJC-1295 and tesamorelin are growth hormone-releasing hormone (GHRH) analogues. They occupy the GHRH receptor on the pituitary and prompt it to release growth hormone it has already made. A 1999 review describes sermorelin, the shortest of the three, as a 29 amino acid analogue of human GHRH that specifically stimulates growth hormone secretion from the anterior pituitary. Prakash 1999 - Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57., in the references below
Ipamorelin works through a different pituitary receptor, later identified as the ghrelin receptor. In the animal study that first characterised it, it produced GH release with a similar potency to GHRP-6. Raun 1998 - Raun K, Hansen BS, Johansen NL et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61., in the references below
In both cases, the pituitary is still the one releasing the hormone. Recombinant HGH removes that step. It is somatropin, manufactured growth hormone with the same amino acid sequence as the pituitary-derived hormone according to its own FDA label, injected directly into the body. The body’s own release pattern, timing and feedback signalling play no part.
Evidence: what’s actually been tested
GH secretagogues:
- Sermorelin: its controlled trials sit in children with growth hormone deficiency, including a six-month comparative trial in 43 prepubertal children. Neyzi 1993 - Neyzi O, Yordam N, Ocal G et al. Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatr Suppl. 1993;388:16-21; discussion 22., in the references below
- Ipamorelin: its human programme reached Phase 2 for postoperative ileus and was discontinued for insufficient efficacy.
- CJC-1295: it has a published pharmacokinetic study in the DAC form only, and no published human data at all for the without-DAC form.
- Tesamorelin: the exception. Its approval rests on randomised controlled trials measuring visceral and liver fat in people with HIV-associated lipodystrophy. Falutz 2010 - Falutz J, Potvin D, Mamputu JC et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22., in the references below Stanley 2014 - Stanley TL, Feldpausch MN, Oh J et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9., in the references below
None of the four has a randomised trial in healthy adults for the muscle, sleep or anti-aging outcomes they are marketed for.
Small or uncontrolled human studies. Too little to settle the question either way. Three of the four secretagogues have human data only in children (sermorelin) or in a discontinued Phase 2 programme (ipamorelin), or no human PK data for one of two marketed forms (CJC-1295). Tesamorelin is approved but only for HIV-associated lipodystrophy.
Recombinant HGH. Decades of randomised trials support its approved uses, per its FDA label:
- paediatric growth hormone deficiency
- Turner syndrome
- Prader-Willi syndrome
- short stature from being born small for gestational age
- idiopathic short stature
- adult-onset or childhood-onset growth hormone deficiency
That evidence base is real and large. It does not extend to a healthy adult using HGH for muscle gain, fat loss or anti-aging. None of those is an approved indication for any brand.
Consistent findings across large trials or meta-analyses. Large randomised trial base underpins each approved indication, per FDA-approved labelling. The rating describes the evidence for those specific, diagnosed conditions - not for use in a healthy adult without one of them.
What the recombinant HGH label actually says
Recombinant human growth hormone is sold under several brand names, including Genotropin, Norditropin, Humatrope, Omnitrope, Saizen, Serostim and Zomacton. Each has its own FDA-approved label and its own specific indications. Genotropin’s current label states it is approved for:
- growth failure due to growth hormone deficiency
- Prader-Willi syndrome
- Turner syndrome
- short stature from being born small for gestational age
- idiopathic short stature in children
- growth hormone deficiency of adult or childhood onset in adults
It carries no boxed warning, but its Warnings and Precautions section is not a light read:
Genotropin is dosed by subcutaneous injection, with the weekly dose divided into six or seven injections, so in practice close to daily. That is a labelled regimen for a diagnosed deficiency, not a protocol to copy.
Regulatory status
Recombinant HGH
US legal status - FDA-approved · prescription only
FDA-approved under multiple brand names, each for its own specific, defined indications. Requires a prescriber. A vial sold without a prescription, or marketed for muscle gain or anti-aging in a healthy adult, is being used outside any approval FDA granted it.
Tesamorelin
US legal status - FDA-approved · prescription only
FDA-approved as Egrifta, for excess visceral abdominal fat in HIV-infected adults with lipodystrophy. Its label states it is not indicated for weight loss management generally.
Sermorelin
CJC-1295 and ipamorelin
US legal status - Research use only
Neither has ever been approved by FDA or any other regulator, for any indication. Both are sold as research chemicals and are not legally marketed for human use.
Sport
Both categories are prohibited. The WADA Prohibited List names growth hormone itself under S2.2.3. It names growth hormone releasing factors under S2.2.4: GHRH analogues such as sermorelin, CJC-1295 and tesamorelin, plus growth hormone secretagogues such as ipamorelin. Both sections are prohibited at all times, in and out of competition. A prescription for tesamorelin or recombinant HGH does not change that for a tested athlete.
What this comparison doesn’t tell you
This page does not say which raises circulating growth hormone more. No published human trial compares any of these four secretagogues against a dose of recombinant HGH head to head. It does not say one is safer than the other for a healthy adult. None of the five has been tested in that population for the outcomes they are marketed for.
“Raises your own GH” is a real mechanism. It is not a demonstrated substitute for an FDA-approved hormone, and it is not evidence-free just because it sounds gentler.
Related
- Sermorelin
- CJC-1295
- Ipamorelin
- Tesamorelin
- Ipamorelin vs sermorelin
- CJC-1295 vs sermorelin
- Tesamorelin vs sermorelin
- Research peptides and the law
Common questions
Is taking a GH secretagogue the same as taking HGH?
No. A secretagogue signals the pituitary to release more of the growth hormone it already makes, through a receptor pathway. Recombinant HGH is that hormone itself, manufactured and injected directly. It bypasses the pituitary step entirely. The two reach a similar endpoint by different mechanisms, and neither is licensed for general enhancement use.
Which growth hormone product is actually FDA-approved?
Two products. One is recombinant human growth hormone, sold as Genotropin, Norditropin, Humatrope, Omnitrope, Saizen, Serostim and Zomacton among others. The other is tesamorelin, sold as Egrifta. Sermorelin was approved once, for children, and its approvals were withdrawn in 2009. CJC-1295 and ipamorelin have never been approved by any regulator.
Does a GH secretagogue raise GH as much as injecting HGH?
I could not locate a published human trial directly comparing any of these secretagogues against a dose of recombinant HGH on the same outcome. Nobody has published that comparison. That does not make the two interchangeable.
Is recombinant HGH safe?
Its own FDA label carries warnings, not a plain safety statement. Two clinical trials cited on the label found higher mortality in critically ill adults given somatropin than placebo. The label also warns of intracranial hypertension and decreased insulin sensitivity. It warns of fatalities in children with Prader-Willi syndrome and risk factors. It says to monitor for second tumours in childhood cancer survivors.
Are GH secretagogues or HGH banned in sport?
Yes, all of them. The WADA Prohibited List names growth hormone itself under S2.2.3 and growth hormone releasing factors, including GHRH analogues and secretagogues, under S2.2.4. Both are prohibited at all times, in and out of competition.
Do HGH peptides really work?
It depends which one. Evidence differs sharply across the four most commonly sold as 'HGH peptides'. Only tesamorelin has randomised trial evidence, and only for one indication: HIV-associated lipodystrophy fat loss, not general anti-aging or muscle claims. Sermorelin's controlled trials are in children with growth hormone deficiency. Ipamorelin's only human trial, for an unrelated use, was discontinued for insufficient efficacy. CJC-1295 has no published human efficacy data at all. None of the four has a published human trial showing it works for the muscle, sleep or anti-aging outcomes they are marketed for.
Is HGH hard on your liver?
No published evidence shows recombinant HGH damages the liver directly, and its FDA label carries no hepatotoxicity warning. The label does note a liver-related interaction. Somatropin increases the activity of the liver's CYP450 enzymes, which can speed up clearance of other drugs those enzymes metabolise, including corticosteroids, sex steroids, anticonvulsants and cyclosporine. That is a drug-interaction caution, not evidence of liver injury.
What is the best HGH peptide?
There isn't one the evidence can name. Of the four most commonly sold as 'HGH peptides', only tesamorelin is FDA-approved, and only for one narrow indication, not muscle gain or anti-aging. Sermorelin, CJC-1295 and ipamorelin have thin or no published human efficacy data for the uses they are sold for. The evidence does not support picking a 'best' among unapproved research chemicals, and this site does not recommend a product or seller.
Which is better, HGH or HGH peptides?
Neither wins outright, because they are tested for different things. Recombinant HGH has decades of randomised trial evidence, but only for defined deficiency states, not general use in a healthy adult. Secretagogues sold as 'HGH peptides' keep the pituitary in the loop in principle. But three of the four have thin or no human efficacy data, and none is approved for the anti-aging, muscle or sleep uses they are marketed for. For an off-label goal, neither is an approved option.
What peptides does Joe Rogan use?
The one peptide Joe Rogan has named in a statement confirmed by two sources is BPC-157. In July 2021 he said on his podcast that it cleared elbow tendonitis within two weeks. He also said he had an NAD drip, which is not a peptide, while ill with COVID-19. Neither statement says what he takes now; see /joe-rogan-peptides/. When podcast guests discuss growth hormone peptides, they usually mean the GH secretagogues compared on this page: sermorelin, CJC-1295, ipamorelin and tesamorelin. Only tesamorelin is FDA-approved, and only for one narrow indication in HIV-associated lipodystrophy. Sermorelin was approved once, for children, and discontinued in 2008. FDA found in 2013 it was not withdrawn for safety or effectiveness reasons. CJC-1295 and ipamorelin have never been approved by any regulator. All three are sold as research chemicals for the uses discussed on podcasts. Each compound's own page sets out its evidence and legal status in full.
Can you legally take HGH?
Yes, with a prescription for an approved indication. Recombinant HGH is FDA-approved under several brands, each for specific, defined conditions such as growth hormone deficiency. A vial bought without a prescription, or marketed for muscle gain or anti-aging in a healthy adult, is outside any approval FDA granted. For tested athletes, growth hormone is prohibited at all times, and a prescription does not change that.
References (10 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Raun K, Hansen BS, Johansen NL et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.StudyPMID 9849822
- 2.Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.StudyPMID 18031173
- 3.Neyzi O, Yordam N, Ocal G et al. Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatr Suppl. 1993;388:16-21; discussion 22.Randomised trialPMID 8329826
- 4.Falutz J, Potvin D, Mamputu JC et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22.Randomised trialPMID 20101189
- 5.Stanley TL, Feldpausch MN, Oh J et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9.Randomised trialPMID 25038357full text
- 6.The Joe Rogan Experience #1683 (with Andrew Huberman), 14 July 2021, episode transcript: Rogan describes elbow tendonitis cleared after starting BPC-157.- Podscripts (episode transcript)other
- 7.GENOTROPIN (somatropin) - full prescribing information, including approved indications, contraindications and Warnings and Precautions.- DailyMed, National Library of Medicinelabel
- 8.EGRIFTA WR (tesamorelin) - full prescribing information, including indication and limitations of use.- DailyMed, National Library of Medicinelabel
- 9.Federal Register, 4 March 2013 - determination that GEREF (sermorelin acetate) was not withdrawn from sale for reasons of safety or effectiveness.- US Government Publishing Office (Federal Register)regulatory
- 10.WADA 2026 Prohibited List, sections S2.2.3 (growth hormone, its analogues and fragments) and S2.2.4 (growth hormone releasing factors) (national anti-doping agency mirror, PDF).- World Anti-Doping Agency (mirrored by the Jamaica Anti-Doping Commission)regulatory